Erythropoietin Resistance in Anemia of Chronic Kidney Disease

Our goal of this pilot project is to identify inflammatory biomarkers that correlate with epo-resistance among CKD patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anemia Erythropoietin Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hematologic Diseases Hemic and Lymphatic Diseases Kidney Diseases Kidney Failure Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Duke University Medical Center Anemia Clinic, Durham, North Carolina, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

prevalent patients greater than or equal to 18 years old with CKD defined as a glomerular filtration rate < 60 cc/min

Exclusion criteria

active GI bleeding or history of GI bleed in the prior 3 months
uncontrolled hyperparathyroidism (PTH>500)
untreated iron deficiency (transferrin saturation < 20% and ferritin < 100
overt infection
active hemolysis
hemoglobinopathies
known adverse response to erythropoietin
prior kidney transplant
aluminum toxicity

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Official study title

Novel Biomarkers of Erythropoietin Resistant Anemia Among Patients With Chronic Kidney Disease

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Sep 10, 2007
Registry last updated: Apr 11, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed